1
|
van Hagen P, Biermann K, Boers JE, Stoss O, Sleddens HF, van Lanschot JJB, Dinjens WNM, Rueschoff J, Wijnhoven BPL. Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma. Dis Esophagus 2014; 28:380-5. [PMID: 24611982 DOI: 10.1111/dote.12204] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed in a subset of esophageal adenocarcinomas. Frequently, biopsy material is used for evaluation of HER2 status. The aim of the study was to determine if HER2 expression in preoperative endoscopic biopsies is representative for the entire tumor. Preoperative endoscopic biopsies and matched resection specimens were collected from 75 patients who underwent esophagectomy for esophageal adenocarcinoma. Immunohistochemical staining (IHC) on HER2 and dual-color in situ hybridization (ISH) were performed. HER2 status was determined by following a clinical algorithm, first determining HER2 overexpression on immunohistochemistry and, when equivocal (2+), determining HER2 amplification on ISH. Seventy-one of 75 (95%) biopsies and 69/75 (92%) resection specimens could be analyzed due to technical failure. HER2 positivity was seen in 18/71 (25%) biopsies and in 15/69 (22%) resection specimens. Overall, HER2 status in the biopsy was concordant with HER2 status in the resection specimen in 94% of cases. Interobserver agreement on IHC scoring for all three observers was 83% in biopsies and 85% in resection specimens. HER2 positivity was detected in 22% of esophageal adenocarcinomas. Although interobserver agreement was moderate, HER2 status of a primary tumor can be reliably determined based on the endoscopically obtained pretreatment biopsy.
Collapse
Affiliation(s)
- P van Hagen
- Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. Ann Oncol 2013; 24:2761-6. [PMID: 23894039 DOI: 10.1093/annonc/mdt275] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Trastuzumab treatment improves survival of HER2-positive primary breast cancer. HER2 staining intensity varies widely in HER2-positive tumours. PATIENTS AND METHODS We investigated whether differences in immunohistochemical (IHC) staining intensity for HER2 in HER2-positive tumors (IHC 3+ or FISH ratio ≥2.0) was associated with prognosis or benefit from trastuzumab treatment in patients randomized to 1 year or no trastuzumab in the HERceptin Adjuvant (HERA) trial. Median follow-up was 2 years. The nested case-control analysis, included 425 patients (cases) with a disease-free survival (DFS) event and two matched controls (no DFS event) per case. Tissue sections stained for HER2 were assessed for HER2 staining intensity by image analysis. RESULTS HER2 staining intensity varied widely and correlated with HER2 gene copy number (Spearman, r = 0.498, P < 0.001) or less closely with HER2/CEP17 FISH ratio (r = 0.396, P < 0.001). We found no significant difference in DFS in the observation arm according to staining intensity (odds ratio [OR] change per 10 unit change in intensity: 1.015, 95% confidence interval [CI] 0.930-1.108) and no impact of staining intensity on benefit derived from 1-year trastuzumab (OR: 1.017, 95% CI 0.925-1.120). CONCLUSIONS Variability in HER2 staining in HER2-positive tumours has no role in clinical management with adjuvant trastuzumab. HERA TRIAL NO NCT00045032.
Collapse
Affiliation(s)
- L Zabaglo
- Academic Department of Biochemistry, Royal Marsden NHS Trust, London
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Rüschoff J, Nagelmeier I, Middel P, Stoss O. Zur Rolle von Her-2/neu in der Karzinogenese des Mammakarzinoms – wann und wo? Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1185923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52:797-805. [DOI: 10.1111/j.1365-2559.2008.03028.x] [Citation(s) in RCA: 868] [Impact Index Per Article: 54.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
5
|
Lordick F, Bang Y, Kang Y, Otero Reyes D, Manikhas G, Shen L, Kulikov E, Stoss O, Jordan B, van Cutsem E. 3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71044-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
6
|
Stoss O, Werther M, Zielinski D, Middel P, Jost N, Rüschoff J, Henkel T, Albers P. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 2007; 11:166-72. [PMID: 17646850 DOI: 10.1038/sj.pcan.4501001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, we aimed to demonstrate that TUR samples can be used to identify significantly affected biological pathways during the switch to HRPC using oligonucleotide microarray analysis. Among the most significantly deregulated pathways in HRPC, we observed an induction of oxidative phosphorylation and a repression of cytoskeletal components.
Collapse
MESH Headings
- Adenocarcinoma/drug therapy
- Adenocarcinoma/genetics
- Adenocarcinoma/metabolism
- Adenocarcinoma/pathology
- Adenocarcinoma/surgery
- Aged
- Aged, 80 and over
- Androgen Antagonists/pharmacology
- Androgen Antagonists/therapeutic use
- Antineoplastic Agents, Hormonal/pharmacology
- Antineoplastic Agents, Hormonal/therapeutic use
- Combined Modality Therapy
- Disease Progression
- Drug Resistance, Neoplasm/genetics
- Gene Expression Profiling/methods
- Gene Expression Regulation, Neoplastic
- Humans
- Male
- Middle Aged
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Oligonucleotide Array Sequence Analysis
- Prostatic Hyperplasia/genetics
- Prostatic Hyperplasia/metabolism
- Prostatic Hyperplasia/pathology
- Prostatic Hyperplasia/surgery
- Prostatic Neoplasms/drug therapy
- Prostatic Neoplasms/genetics
- Prostatic Neoplasms/metabolism
- Prostatic Neoplasms/pathology
- Prostatic Neoplasms/surgery
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- RNA, Messenger/isolation & purification
- RNA, Neoplasm/biosynthesis
- RNA, Neoplasm/genetics
- RNA, Neoplasm/isolation & purification
- Signal Transduction/genetics
- Transcription, Genetic
- Transurethral Resection of Prostate
Collapse
Affiliation(s)
- O Stoss
- TARGOS Molecular Pathology GmbH, Kassel, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Stoss O, Jost N, Czeloth K, Rüschoff J, Henkel T, Albers P. [Gene expression profile in hormone refractory prostate cancer]. Urologe A 2007; 46:1117-9. [PMID: 17639295 DOI: 10.1007/s00120-007-1447-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- O Stoss
- Institut für Pathologie und Molekularpathologie, Klinikum Kassel GmbH, Kassel
| | | | | | | | | | | |
Collapse
|
8
|
León-Chong J, Lordick F, Kang YK, Park SR, Bang YJ, Sawaki A, Van Cutsem E, Stoss O, Jordan BW, Feyereislova A. HER2 positivity in advanced gastric cancer is comparable to breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15057] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15057 Background: Accurate HER2 testing is required to identify patients eligible for treatment with trastuzumab (Herceptin®). HER2 positivity is reported as 6–35% in gastric cancer (GC). This range is due to small sample sets and differing methods of evaluation or scoring. A specific HER2-testing process was established for the Phase III ToGA trial, which is evaluating trastuzumab added to chemotherapy in HER2-positive advanced GC. Methods: A validation study was completed to standardise IHC (HercepTest™) and FISH (PharmDx™) protocols, and to establish a scoring system specific for GC (M Hofmann et al. ASCO Gastrointestinal Cancers Symposium 2006. Abstract no. 24). Tumour samples for ToGA were then centrally tested by both IHC and FISH to identify patients eligible for enrolment. Results: To date, 1024 tumour samples have been assessed (243 HER2 positive and 781 HER2 negative) giving an overall HER2-positivity rate of 23.7%. Both IHC and FISH results are available for 960 patients, with 87% concordance. Differences were largely due to FISH-positive cases that were IHC 0/1+. HER2 positivity differed significantly by histological subtype: 36% in intestinal, 7% in diffuse and 23% in mixed. HER2 positivity also varied according to the site of the tumour: 36% (8/22) for gastro-oesophageal junction tumours and 21% (60/291) for gastric tumours. Sample numbers were very small so these results must be treated with caution. The HER2- positivity rate was similar in specimens obtained by biopsy (168/689; 24%) and surgery (71/322; 22%). Conclusions: Using validated methodology and based on the large sample set from the ongoing ToGA trial, the HER2-positivity rate observed in advanced GC is as high as in breast cancer: ∼24%. The first efficacy data from ToGA are expected in 2009. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. León-Chong
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - F. Lordick
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - Y. K. Kang
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - S. R. Park
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - Y. J. Bang
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - A. Sawaki
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - E. Van Cutsem
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - O. Stoss
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - B. W. Jordan
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| | - A. Feyereislova
- National Institute for Neoplastic Diseases, Surquillo, Peru; Munich University of Technology, Munich, Germany; Asan Medical Center, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; University Hospital Gasthuisberg, Leuven, Belgium; TARGOS Molecular Pathology GmbH, Kassel, Germany; F. Hoffmann-La Roche, Basel, Switzerland
| |
Collapse
|
9
|
Stoss O, Zielinski D, Czeloth K, Middel P, Henkel T, Albers P. Molecular analysis of hormone refractory prostate cancer biopsies supports the rationale of using mTOR inhibitors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21126 Background: The aim of our group is to identify molecular signatures in samples of hormone refractory prostate cancer (HRPC) patients (pts) that lead to novel rationales for medical treatment. We have previously shown that transurethral resections (TUR) of the prostate in HRPC pts are useful specimens for gene expression profiling using microarrays (ASCO 2006). Aim of this study was to prove the feasibility of gene expression profiling on prostate biopsies and to develop a standardised tissue handling protocol in order to facilitate multicenter research. Methods: Biopsy material and corresponding TUR chips or classical specimens from 8 pts with HRPC, 13 pts with localized PCA, 6 pts with benign prostatic hyperplasia (BPH) and 11 pts without cancer or BPH were investigated and compared. The tumor type and content was evaluated by a pathologist. Tissues were preserved in liquid nitrogen or RNAlater. Different tissue lysis and RNA purification methods were compared by the quantity (NanoDrop measurement) and quality (Bioanalyser, Agilent) of isolated RNA. Gene expression profiling occurred on Affymetrix HG-FOCUS arrays. Results: Most reliable gene expression results were obtained by biopsy lysis in Trizol using the QIAshredder. A total of more than 1 μg RNA was isolated from one biopsy. RNA quality fulfilled pre-defined criteria such as a 28S/18S rRNA ratio of > 0.8, an area under the curve of > 10% and a RNA integrity number > 6.5. A comparison of HRPC and PCA samples clearly confirmed previous results of a deregulation of protein biosynthesis (translation initiation and elongation factors, ribosome biogenesis) and PI3K signalling pathway components. Conclusions: Gene expression profiling supports the induction of the PI3K-AKT-mTOR pathway in HRPC. A standardised protocol for gene expression profiling from prostate biopsy samples applicable for translational research programs within multicenter clinical trials is now available. As a part of a clinical phase II trial that aims to investigate survival benefits on HRPC pts treated with docetaxel ± RAD001, a translational research program is now set up in parallel to identify biomarkers for response prediction using microarray gene expression analysis from prostate biopsies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Stoss
- Klinikum Kassel GmbH, Kassel, Germany
| | | | | | - P. Middel
- Klinikum Kassel GmbH, Kassel, Germany
| | - T. Henkel
- Klinikum Kassel GmbH, Kassel, Germany
| | - P. Albers
- Klinikum Kassel GmbH, Kassel, Germany
| |
Collapse
|
10
|
Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T, Kaufmann M, Henkel T, Rüschoff J. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2007; 61:89-94. [PMID: 17412870 DOI: 10.1136/jcp.2006.043562] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIMS To investigate the correlation between centrally assessed human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) results and response to treatment of patients with metastatic breast cancer enrolled in a first-line, phase II, open-label, 3-weekly trastuzumab (Herceptin) monotherapy trial (WO16229). METHODS Samples from participants in the WO16229 trial were collected and tumour HER2 status determined by IHC and FISH. HER2 test results were interpreted according to manufacturers' test kit protocols. Responders were defined as patients showing either partial or complete responses. RESULTS Response data were available for 103/105 patients; centrally confirmed HER2 status was available for 95 patients. Intra-laboratory concordance for central IHC and FISH results was 93%. Complete responses were seen in two patients; their samples were IHC 3+ and FISH positive. Partial responses were seen in 17 patients; all were IHC 3+ and 14 were FISH positive. IHC and FISH showed 100% and 84.2% sensitivity, respectively, in determining response to trastuzumab. Polysomy was observed in 27% of patients; six responded to trastuzumab treatment. All six responders showed HER2 overexpression (IHC 3+) and HER2 gene amplification; two were FISH negative due to chromosome 17 polysomy. CONCLUSIONS HER2 determination by IHC and FISH correlates with clinical response data in the WO16229 trial with high concordance of IHC and FISH results. Polysomy is the major cause of response in FISH-negative cases; polysomic cases should be retested by strictly standardised IHC.
Collapse
Affiliation(s)
- M Hofmann
- Institute of Pathology and Biomedical Research, Klinikum Kassel GmbH, Kassel, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Hünerbein R, Talartschik J, Stoss O, Kuhn FP. Radiologische Interventionen am insuffizienten Dialyseshunt. Klinischer Verlauf von 110 Patienten. ROFO-FORTSCHR RONTG 2007. [DOI: 10.1055/s-2007-977148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Stoss O, Albers P, Werther M, Zielinsky D, Jost N, Rueschoff J, Henkel T. Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4641 Background: Patients with metastatic carcinoma of the prostate (CaP) develop after a mean of 15 months resistance to hormone ablation therapy. However, the underlying molecular mechanisms are still unknown. Our goal was to identify the transcriptional changes that are characteristic for the transition to hormone resistant prostate cancer (HRPC) using oligonucleotide microarrays. Here, we report the attempt to profile fresh frozen tissue obtained by palliative transurethral resection (TUR) in patients with HRPC and concomittant urinary obstruction. Methods: Indications for palliative TUR were locally progressive tumors with obstruction and voiding problems. HRPC was defined according to the criteria of Scher et al. 1995. Samples of 8 HRPC patients were compared to tissues from 8 hormone-sensitive CaP patients including biological and technical replicates. All tissue samples had been pathologically evaluated. Only macrodissected prostate samples with at least 70% tumor content were used for RNA extraction. RNA quality was controlled using the Bioanalyzer Nanochip (Agilent Technologies, Palo Alto). Expression analysis was performed on Affymetrix oligonucleotide arrays. Results: We identified 323 genes being significantly deregulated (corrected p-value <0.05, false discovery rate <0.05). These genes were mapped to cellular pathways using the KEGG annotation and the most significantly deregulated pathways were identified. Deregulation of metabolic pathways included fatty acid metabolism as well as oxidative phosphorylation and ATP synthesis. Cell cycle control seems to be further suppressed by the downregulation of JNK-pathway via MEKK4 and JUND, the downregulation of p21 (CDKN1A) and the induction of Cylcin D1. We also present evidence for a significant downregulation of actin cyctoskeleton components. Deregulated genes likely to be specific for the transition from prostate carcinoma to HRPC will be presented. Conclusions: Gene expression profiling has been successfully standardised using fresh TUR material of HRPC patients. Deregulated genes have been mapped to specific signal transduction pathways. On this platform, clinical trials in patients with HRPC using specific inhibitors of cell signalling are being developed. [Table: see text]
Collapse
Affiliation(s)
- O. Stoss
- Targos Molecular Pathology, Kassel, Germany; Department of Urology, Kassel, Germany; Institute of Pathology, Kassel, Germany
| | - P. Albers
- Targos Molecular Pathology, Kassel, Germany; Department of Urology, Kassel, Germany; Institute of Pathology, Kassel, Germany
| | - M. Werther
- Targos Molecular Pathology, Kassel, Germany; Department of Urology, Kassel, Germany; Institute of Pathology, Kassel, Germany
| | - D. Zielinsky
- Targos Molecular Pathology, Kassel, Germany; Department of Urology, Kassel, Germany; Institute of Pathology, Kassel, Germany
| | - N. Jost
- Targos Molecular Pathology, Kassel, Germany; Department of Urology, Kassel, Germany; Institute of Pathology, Kassel, Germany
| | - J. Rueschoff
- Targos Molecular Pathology, Kassel, Germany; Department of Urology, Kassel, Germany; Institute of Pathology, Kassel, Germany
| | - T. Henkel
- Targos Molecular Pathology, Kassel, Germany; Department of Urology, Kassel, Germany; Institute of Pathology, Kassel, Germany
| |
Collapse
|
13
|
Gaiser T, Hofmann M, Stoss O, Henkel T, Rüschoff J. [Her-2/neu analysis--new data?]. Verh Dtsch Ges Pathol 2006; 90:107-13. [PMID: 17867586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Her-2 status determination is an essential prerequisite before considering patient eligibility for treatment with trastuzumab. Currently the most common techniques to assess Her-2 status in routine practice are immunohistochemistry (IHC) and dual color FISH for receptor expression and gene amplification analysis, respectively. Despite both methods are well-established in breast cancer there are a variety of yet unsolved questions: 1. Do we really need IHC since interlab variation is still quite high (up to 30%)? 2. Are FISH and CISH equivalent techniques? 3. Are there any precautions to be taken if Her-2 is tested in non-breast cancer samples? 4. What is the value of Her-2 status in blood serum (ELISA)? 5. Do we get better response prediction if new Her2 antibodies, other techniques such as quantitative (q) RT-PCR or multiparameter assays according to downstream signalling pathways are applied? 6. Is Her-2 status still predictive when other therapeutic antibodies than trastuzumab (e. g. pertuzumab) or kinase inhibitors (e. g. lapatinib) are used? These questions will be discussed under the review of the recent literature and under own experiences obtained either by centralized Her-2 assessment in a variety of breast and non-breast cancer therapy studies and within international ring studies between reference labs from Australia (M. Bilous), Canada (W. Hanna), France (F. Penault-Llorcoa), Great Britain (M. Dowsett), Japan (R. Y. Osamura), and Netherlands (M. v. d. Vijver) in which we participated.
Collapse
Affiliation(s)
- T Gaiser
- Institut für Pathologie, Klinikum Kassel, Kassel
| | | | | | | | | |
Collapse
|
14
|
Albers P, Thiele M, Stoss O, Jost N, Schmidtgen C, Rueschoff J, Henkel T. Gene expression analysis of hormone-refractory prostate cancer in transurethral resection samples. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - N. Jost
- Klin Kassel, Kassel, Germany
| | | | | | | |
Collapse
|
15
|
Stoss O, Olbrich M, Hartmann AM, Konig H, Memmott J, Andreadis A, Stamm S. The STAR/GSG family protein rSLM-2 regulates the selection of alternative splice sites. J Biol Chem 2001; 276:8665-73. [PMID: 11118435 DOI: 10.1074/jbc.m006851200] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
We identified the rat Sam68-like mammalian protein (rSLM-2), a member of the STAR (signal transduction and activation of RNA) protein family as a novel splicing regulatory protein. Using the yeast two-hybrid system, coimmunoprecipitations, and pull-down assays, we demonstrate that rSLM-2 interacts with various proteins involved in the regulation of alternative splicing, among them the serine/arginine-rich protein SRp30c, the splicing-associated factor YT521-B and the scaffold attachment factor B. rSLM-2 can influence the splicing pattern of the CD44v5, human transformer-2beta and tau minigenes in cotransfection experiments. This effect can be reversed by rSLM-2-interacting proteins. Employing rSLM-2 deletion variants, gel mobility shift assays, and linker scan mutations of the CD44 minigene, we show that the rSLM-2-dependent inclusion of exon v5 of the CD44 pre-mRNA is dependent on a short purine-rich sequence. Because the related protein of rSLM-2, Sam68, is believed to play a role as an adapter protein during signal transduction, we postulate that rSLM-2 is a link between signal transduction pathways and pre-mRNA processing.
Collapse
Affiliation(s)
- O Stoss
- Max-Planck Institute of Neurobiology, Am Klopferspitz 18a, D-82152 Martinsried, the Forschungszentrum Karlsruhe, Institut für Genetik, Postfach 3640, D-76021 Karlsruhe, Germany
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
We compiled a comprehensive database of alternative exons from the literature and analyzed them statistically. Most alternative exons are cassette exons and are expressed in more than two tissues. Of all exons whose expression was reported to be specific for a certain tissue, the majority were expressed in the brain. Whereas the length of constitutive exons follows a normal distribution, the distribution of alternative exons is skewed toward smaller ones. Furthermore, alternative-exon splice sites deviate more from the consensus: their 3' splice sites are characterized by a higher purine content in the polypyrimidine stretch, and their 5' splice sites deviate from the consensus sequence mostly at the +4 and +5 positions. Furthermore, for exons expressed in a single tissue, adenosine is more frequently used at the -3 position of the 3' splice site. In addition to the known AC-rich and purine-rich exonic sequence elements, sequence comparison using a Gibbs algorithm identified several motifs in exons surrounded by weak splice sites and in tissue-specific exons. Together, these data indicate a combinatorial effect of weak splice sites, atypical nucleotide usage at certain positions, and functional enhancers as an important contribution to alternative-exon regulation.
Collapse
Affiliation(s)
- S Stamm
- Institute of Biochemistry, University of Erlangen-Nuremberg, Erlangen, Germany.
| | | | | | | | | | | |
Collapse
|
17
|
Abstract
The exact mechanisms leading to alternative splice site selection are still poorly understood. However, recently cotransfection studies in eukaryotic cells were successfully used to decipher contributions of RNA elements (cis-factors), their interacting protein components (trans-factors) or the cell type to alternative pre-mRNA splicing. Splice factors often work in a concentration dependent manner, resulting in a gradual change of alternative splicing patterns of a minigene when the amount of a trans-acting protein is increased by cotransfections. Here, we give a detailed description of this technique that allows analysis of large gene fragments (up to 10-12 kb) under in vivo condition. Furthermore, we provide a summary of 44 genes currently investigated to demonstrate the general feasibility of this technique.
Collapse
Affiliation(s)
- O Stoss
- Max-Planck Institute of Neurobiology, Am Klopferspitz 18a, D-82152, Martinsried, Germany
| | | | | | | | | |
Collapse
|
18
|
Stoss O, Schwaiger FW, Cooper TA, Stamm S. Alternative splicing determines the intracellular localization of the novel nuclear protein Nop30 and its interaction with the splicing factor SRp30c. J Biol Chem 1999; 274:10951-62. [PMID: 10196175 DOI: 10.1074/jbc.274.16.10951] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We report on the molecular cloning of a novel human cDNA by its interaction with the splicing factor SRp30c in a yeast two-hybrid screen. This cDNA is predominantly expressed in muscle and encodes a protein that is present in the nucleoplasm and concentrated in nucleoli. It was therefore termed Nop30 (nucleolar protein of 30 kDa). We have also identified a related cDNA with a different carboxyl terminus. Sequencing of the NOP gene demonstrated that both cDNAs are generated by alternative 5' splice site usage from a single gene that consists of four exons, spans at least 1800 nucleotides, and is located on chromosome 16q21-q23. The alternative 5' splice site usage introduces a frameshift creating two different carboxyl termini. The carboxyl terminus of Nop30 is rich in serines and arginines and has been found to target the protein into the nucleus, whereas its isoform is characterized by proline/glutamic acid dipeptides in its carboxyl terminus and is predominantly found in the cytosol. Interaction studies in yeast, in vitro protein interaction assays, and co-immunoprecipitations demonstrated that Nop30 multimerizes and binds to the RS domain of SRp30c but not to other splicing factors tested. Overexpression of Nop30 changes alternative exon usage in preprotachykinin and SRp20 reporter genes, suggesting that Nop30 influences alternative splice site selection in vivo.
Collapse
Affiliation(s)
- O Stoss
- Max-Planck Institute of Neurobiology, Am Klopferspitz 18a, D-82152 Martinsried, Germany
| | | | | | | |
Collapse
|
19
|
Stoss O, Mogk A, Schumann W. Integrative vector for constructing single-copy translational fusions between regulatory regions of Bacillus subtilis and the bgaB reporter gene encoding a heat-stable beta-galactosidase. FEMS Microbiol Lett 1997; 150:49-54. [PMID: 9163905 DOI: 10.1111/j.1574-6968.1997.tb10348.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Here we report on the construction of two integrative plasmids for Bacillus subtilis allowing in vitro construction of translational fusions. Both plasmids contain two cassettes in tandem: the bgaB gene encoding a heat-stable beta-galactosidase devoid of its own regulatory sequences and the first two codons followed by a neomycin-resistance gene for selection in B. subtilis. Both cassettes are flanked by the 3'- and 5'-end of the amyE gene (encoding alpha-amylase) allowing integration of both cassettes at the amyE locus of the B. subtilis chromosome. For propagation in Escherichia coli, the plasmids contain the pBR322 origin of DNA replication and the beta-lactamase-encoding gene. Whereas one vector needs a promoter, a Shine-Dalgarno sequence and the beginning of a gene fused in-frame to bgaB, the other one already carries a constitutive promoter. The versatility of the gene fusion vectors was demonstrated by the integration of the regulatory regions of the dnaK and the cat-86 genes. In the first case, heat-inducible expression was found, and by comparison with an operon fusion, it seems that the dnaK operon is regulated at both the transcriptional and the posttranscriptional level. In the second case, chloramphenicol-inducible regulation of the gene fusion could be demonstrated.
Collapse
Affiliation(s)
- O Stoss
- Institute of Genetics, University of Bayreuth, Germany
| | | | | |
Collapse
|